Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717532 · ClinicalTrials.gov registry record · NA
Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03717532: Clinical Trial NA study, sponsored by NYU Langone Health.
NCT03717532 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03717532, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of blood restriction therapy by comparing increase in muscle mass and strength in patients that receive blood restriction therapy to patients who receive a placebo.
Primary Outcome
Biodex dynamometer is used under standard of care to measure the extensor strength of both legs and have bilateral thigh circumference measured
Interventions
- PROCEDURE Placebo
- PROCEDURE Personalized Tourniquet System for Blood Flow Restriction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2019-11-01 |
| Phase | NA |
Why NCT03717532 stopped before completion
NCT03717532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03717532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03717532 about?
NCT03717532 is a clinical study titled "Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome". The purpose of this study is to determine the efficacy of blood restriction therapy by comparing increase in muscle mass and strength in patients that receive blood restriction therapy to patients who receive a placebo.
What is the current status of trial NCT03717532?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2019-02-01. Estimated completion is 2019-11-01.
What interventions are being tested in trial NCT03717532?
The interventions under investigation include: Placebo (PROCEDURE), Personalized Tourniquet System for Blood Flow Restriction (PROCEDURE).
Who is sponsoring clinical trial NCT03717532?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03717532's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI